title: Update on systemic vasculitides.
abstract: Management of systemic vasculitis has been revolutionised over the last decade with the introduction of targeted biological agents. With an increase in both the prevalence and the recognition of vasculitis as well as the high cost of these agents, it is important to ensure their most optimal utilisation. The goals of vasculitis therapy include the induction and maintenance of remissions, preventing relapses, reducing the toxicity of therapy with the aim of reducing morbidity and mortality as well as improving the quality of life of those afflicted. This review focuses on the recent advances in the diagnosis, surveillance and treatment of these conditions.
authors.affiliation: Department of Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
authors.forename: Siddiq
authors.initials: S
authors.lastname: Anwar
authors.affiliation: Immunology Department, Frimley Park Hospital, Frimley, UK.
authors.forename: M Yousuf
authors.identifier: http://orcid.org/0000-0002-0051-2423
authors.initials: MY
authors.lastname: Karim
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000276:immunology; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000502:physiology; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D053264:B-Cell Activating Factor / Q000378:metabolism; D001685:Biological Factors / Q000627:therapeutic use*; D003170:Complement Pathway, Alternative / Q000502:physiology; D032921:Consensus; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015848:Interleukin-5 / Q000276:immunology; D051907:Lysosomal Membrane Proteins / Q000276:immunology; D057285:Precision Medicine / Q000379:methods; D044087:Receptor, Anaphylatoxin C5a / Q000037:antagonists & inhibitors; D051116:Receptors, Scavenger / Q000276:immunology; D000069283:Rituximab / Q000627:therapeutic use; D056647:Systemic Vasculitis / Q000188:drug therapy* / Q000209:etiology; D000079424:Tumor Necrosis Factor Inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor; D001685:Biological Factors; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D015848:Interleukin-5; D051907:Lysosomal Membrane Proteins; D044087:Receptor, Anaphylatoxin C5a; D051116:Receptors, Scavenger; C074299:SCARB2 protein, human; D000079424:Tumor Necrosis Factor Inhibitors; D000069283:Rituximab; C511911:belimumab; C502936:tocilizumab
keywords: ANTIBODIES; AUTOANTIBODY; IMMUNOLOGY; LYMPHOCYTES; VASCULITIS